Literature DB >> 10221355

The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

A L van Steveninck1, B N van Berckel, R C Schoemaker, D D Breimer, J M van Gerven, A F Cohen.   

Abstract

Various methods are used to quantify sedative drug effects, but it is unknown how these surrogate measures relate to clinically relevant sleepiness. This study assessed the sensitivity of different surrogates of sedation to clinically relevant sleepiness induced by sleep deprivation. Nine healthy volunteers completed a balanced three-way cross-over study with 1-week wash-out periods. Adaptive tracking, smooth-pursuit and saccadic eye movements, body sway, digit symbol substitution (DSST), visual analogue scales (VAS) and electroencephalograms (EEG) were evaluated on three occasions: (1) during the day after normal sleep, (2) during wakefulness at night; and (3) during the day after a night of sleep deprivation. VAS of alertness showed a gradual decline at night and a constant average reduction of 38 percent [95% Confidence intervals (CI), 28-47%] during the day after sleep deprivation. Average mood scores diminished by 14 percent (95%, CI 2-24%) during the day after sleep deprivation. Adaptive tracking, saccadic eye movements and body sway tended to deteriorate at night, but overall this was not statistically significant. After a night of sleep deprivation, adaptive tracking decreased by 21 percent (95% CI, 11-30%), saccadic eye movements decreased by 9-10 percent (95% CI, 5-13%/6-15%) and body sway increased by 37 percent (95% CI, 5-79%). In contrast, EEG beta2-amplitudes declined significantly at night by 18 percent (95% CI, 6-29%), without changes during the day after sleep deprivation. Smooth pursuit, DSST and other EEG-amplitudes remained unchanged. These results emphasize that reductions in adaptive tracking, saccadic peak velocity and body sway caused by sedative drugs really reflect sedation. They also provide a level of clinical significance for these surrogates of sedation. EEG parameters and smooth pursuit were unaffected by sleep deprivation, so drug-induced changes in these measures may not reflect sedation in a stricter sense. The motivation and alertness necessary for DSST may overcome mild sedation.

Entities:  

Mesh:

Year:  1999        PMID: 10221355     DOI: 10.1177/026988119901300102

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  30 in total

Review 1.  Biomarkers for the effects of antipsychotic drugs in healthy volunteers.

Authors:  S J de Visser; J van der Post; M S Pieters; A F Cohen; J M van Gerven
Journal:  Br J Clin Pharmacol       Date:  2001-02       Impact factor: 4.335

Review 2.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

3.  Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension.

Authors:  Michiel J B Kemme; Jeroen P vd Post; Rik C Schoemaker; Matthias Straub; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

4.  The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693.

Authors:  J P van der Post; S J de Visser; M L de Kam; M Woelfler; D C Hilt; J Vornov; E S Burak; E Bortey; B S Slusher; T Limsakun; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

5.  Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.

Authors:  Remco W M Zoethout; Rik C Schoemaker; Lineke Zuurman; Hans van Pelt; Albert Dahan; Adam F Cohen; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

6.  Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Authors:  Marieke Liem-Moolenaar; Mandana Rad; Stefano Zamuner; Adam F Cohen; Francesca Lemme; Kari L Franson; Joop M A van Gerven; Emilio Merlo Pich
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

7.  First-in-human study with ACT-539313, a novel selective orexin-1 receptor antagonist.

Authors:  Priska Kaufmann; Marion Ort; Georg Golor; Rüdiger Kornberger; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2020-03-06       Impact factor: 4.335

8.  The central nervous system effects of the partial GABA-Aα2,3 -selective receptor modulator AZD7325 in comparison with lorazepam in healthy males.

Authors:  Xia Chen; Gabriël Jacobs; Marieke de Kam; Judith Jaeger; Jaakko Lappalainen; Paul Maruff; Mark A Smith; Alan J Cross; Adam Cohen; Joop van Gerven
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

9.  Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Authors:  Benjamin Berger; Sander Brooks; Rob Zuiker; Muriel Richard; Clemens Muehlan; Jasper Dingemanse
Journal:  CNS Drugs       Date:  2020-11-18       Impact factor: 5.749

10.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.